Home > Clinical drug testing in primary care.

Center for Substance Abuse Treatment. (2012) Clinical drug testing in primary care. Rockville, MD: Substance Abuse and Mental Health Services Administration. Technical assistance publication (TAP) series 32. Publication no. SMA12-4668.

[img] PDF (Clinical drug testing in primary care.) - Published Version

Chapter 1—Introduction
• Audience for the TAP
• Organization of the TAP
• Reasons To Use Clinical Drug Testing in Primary Care
• Primary Care and Substance Use Disorders
• Development of Drug Testing
• Workplace Drug Testing
• Drug Testing in Substance Abuse Treatment and Healthcare Settings
• Differences Between Federal Workplace Drug Testing and Clinical Drug Testing
• Caution

Chapter 2—Terminology and Essential
Concepts in Drug Testing
• Drug Screening and Confirmatory Testing
• Testing Methods
• Test Reliability
• Window of Detection
• Cutoff Concentrations
• Cross-Reactivity
• Drug Test Panels
• Test Matrix
• Point-of-Care Tests
• Adulterants
• Specimen Validity Tests
• Clinical Drug Testing in Primary Care

Chapter 3—Preparing for Drug Testing
• Deciding Which Drugs To Screen and Test For
• Choosing a Matrix
• Specimen Availability
• Oral Fluid
• Sweat
• Blood
• Hair
• Breath
• Meconium
• Selecting the Initial Testing Site: Laboratory or Point-of-Care
• Collection Devices
• Laboratory Tests
• Advantages and Disadvantages of Testing in a Laboratory
• Considerations for Selecting a Laboratory
• Point-of-Care Tests
• Advantages and Disadvantages of POCTs
• Considerations for Selecting POCT Devices
• Implementing Point-of-Care Testing
• Preparing Clinical and Office Staffs for Testing
• Preparing a Specimen Collection Site

Chapter 4—Drug Testing in Primary Care
• Uses of Drug Testing in Primary Care
• Monitoring Prescription Medication Use
• Management of Chronic Pain With Opioids
• Evaluation of Unexplained Symptoms or Unexpected Responses to Treatment
• Patient Safety
• Pregnancy
• Psychiatric Care
• Monitoring Office-Based Pharmacotherapy for Opioid Use Disorders
• Detection of Substance Use Disorders
• Initial Assessment of a Person With a Suspected SUD
• Talking With Patients About Drug Testing
• Cultural Competency and Diversity
• Monitoring Patients
• Patients With an SUD
• Monitoring Patients Receiving Opioids for Chronic Noncancer Pain
• Ensuring Confidentiality and 42 CFR Part 2
• Preparing for Implementing Drug Testing
• Collecting Specimens
• Conducting POCTs
• Interpreting Drug Test Results
• Result: Negative Specimen
• Result: Positive Specimen
• Result: Adulterated or Substituted Specimen
• Result: Dilute Specimen
• Result: Invalid Urine Specimen
• Frequency of Testing
• Documentation and Reimbursement
• Documentation
• Reimbursement

Chapter 5—Urine Drug Testing for Specific Substances
• Window of Detection
• Specimen Collection
• Adulteration, Substitution, and Dilution
• Adulteration
• Substitution
• Dilute Specimens
• Cross-Reactivity
• Alcohol
• Amphetamines
• Barbiturates
• Benzodiazepines
• Cocaine
• Marijuana/Cannabis
• Opioids
• Other Substances of Abuse
• Club Drugs
• Inhalants

Appendix A—Bibliography 63
Appendix B—Laboratory Initial Drug-Testing Methods
Appendix C—Laboratory Confirmatory Drug-Testing Methods
Appendix D—Laboratory Specimen Validity-Testing Methods
Appendix E—Glossary
Appendix F—Expert Panel
Appendix G—Consultants and Field Reviewers

Item Type
Publication Type
International, Guideline, Report
Drug Type
All substances
Intervention Type
Treatment method, Screening / Assessment
Identification #
Technical assistance publication (TAP) series 32. Publication no. SMA12-4668
96 p.
Substance Abuse and Mental Health Services Administration
Corporate Creators
Center for Substance Abuse Treatment
Place of Publication
Rockville, MD
Accession Number
HRB (Electronic Only)
Related (external) link

Repository Staff Only: item control page